Downregulation of miR-588 is associated with tumor progression and unfavorable prognosis in patients with osteosarcoma
- PMID: 33884030
- PMCID: PMC8056108
- DOI: 10.3892/etm.2021.10024
Downregulation of miR-588 is associated with tumor progression and unfavorable prognosis in patients with osteosarcoma
Abstract
Osteosarcoma (OS) is a primary malignant tumor characterized by a high metastatic potential and poor prognosis. The dysregulation of miR-588 has been demonstrated to serve crucial roles in the progression of numerous types of cancer. The present study aimed to investigate the expression and function of miR-588 in the development of OS. To do so, clinical samples were collected and analyzed, and in vitro experiments were conducted. A total of 104 patients with OS were recruited between 2012 and 2014. The expression of miR-588 was analyzed by reverse transcription quantitative PCR. The association between miR-588 expression and the clinicopathological characteristics and survival rate of patients with OS was evaluated. Furthermore, Cell Counting Kit-8 and Transwell assays were used to evaluate the effect of miR-588 on the proliferation and the migratory and invasive abilities of various OS cell lines. The results demonstrated that miR-588 expression in OS tissues and cells was significantly lower compared with normal tissues and cells. In addition, miR-588 expression was closely associated with the Musculoskeletal Tumor Society (MSTS) staging of patients with OS. miR-588 expression and MSTS staging were therefore considered as independent indicators for the prognosis of patients with OS. In addition, miR-588 downregulation significantly stimulated the proliferation and migratory and invasive abilities of OS cells. Taken together, these findings indicated that miR-588 may serve as an independent prognostic factor and tumor suppressor in OS.
Keywords: development; miR-588; osteosarcoma; prognosis; tumor progression.
Copyright © 2021, Spandidos Publications.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures




Similar articles
-
Downregulation of miR-136 promotes the progression of osteosarcoma and is associated with the prognosis of patients with osteosarcoma.Oncol Lett. 2019 Jun;17(6):5210-5218. doi: 10.3892/ol.2019.10203. Epub 2019 Apr 1. Oncol Lett. 2019. PMID: 31186737 Free PMC article.
-
MiR-199b-5p promotes malignant progression of osteosarcoma by regulating HER2.J BUON. 2018 Nov-Dec;23(6):1816-1824. J BUON. 2018. PMID: 30610808
-
Upregulation of miR-1307-3p and its function in the clinical prognosis and progression of gastric cancer.Oncol Lett. 2021 Feb;21(2):91. doi: 10.3892/ol.2020.12352. Epub 2020 Dec 6. Oncol Lett. 2021. PMID: 33376524 Free PMC article.
-
Increased Expression of microRNA-199b-5p Associates with Poor Prognosis Through Promoting Cell Proliferation, Invasion and Migration Abilities of Human Osteosarcoma.Pathol Oncol Res. 2016 Apr;22(2):253-60. doi: 10.1007/s12253-015-9901-3. Epub 2015 Jun 18. Pathol Oncol Res. 2016. PMID: 26183062
-
Downregulation of microRNA-605 indicates poor prognosis and promotes the progression of osteosarcoma.Oncol Lett. 2020 Dec;20(6):370. doi: 10.3892/ol.2020.12233. Epub 2020 Oct 19. Oncol Lett. 2020. PMID: 33154768 Free PMC article.
Cited by
-
Analysis of microRNA expression in CD133 positive cancer stem‑like cells of human osteosarcoma cell line MG-63.PeerJ. 2021 Sep 3;9:e12115. doi: 10.7717/peerj.12115. eCollection 2021. PeerJ. 2021. PMID: 34557357 Free PMC article.
-
CircORC2 promoted proliferation and inhibited the sensitivity of osteosarcoma cell lines to cisplatin by regulating the miR-485-3p/TRIM2 axis.J Cell Commun Signal. 2024 Apr 25;18(2):e12029. doi: 10.1002/ccs3.12029. eCollection 2024 Jun. J Cell Commun Signal. 2024. PMID: 38946721 Free PMC article.
-
CircECE1 promotes osteosarcoma progression through regulating RAB3D by sponging miR-588.J Orthop Surg Res. 2023 Aug 9;18(1):587. doi: 10.1186/s13018-023-04045-4. J Orthop Surg Res. 2023. PMID: 37559140 Free PMC article.
-
MiR-588 acts as an oncogene in ovarian cancer and increases the radioresistance of ovarian cancer cells.J Radiat Res. 2023 May 6;64(3):558-68. doi: 10.1093/jrr/rrad033. Online ahead of print. J Radiat Res. 2023. PMID: 37154623 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources